Workspaces
Log in Sign up

European CHMP Recommends Revoking Amgen's Tavneos (avacopan) Marketing Authorization Over Data Integrity and GCP Breaches

Updated

Sources

European CHMP Recommends Revoking Amgen's Tavneos (avacopan) Marketing Authorization Over Data Integrity and GCP Breaches

The global regulatory crisis surrounding Amgen's rare autoimmune drug Tavneos (avacopan) has intensified dramatically. On June 26, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the drug's marketing authorization in the European Union.12 This decision follows a formal review of data integrity issues within the pivotal 331-patient ADVOCATE study, which originally secured the drug's EU approval in 2022.

The CHMP concluded that the ADVOCATE trial was conducted in breach of Good Clinical Practice (GCP) guidelines and that the efficacy data provided could no longer be trusted.3 Consequently, the committee determined that the benefits of Tavneos no longer outweigh its risks. No new patients will be started on the drug in the EU, and current patients are advised to consult their physicians.

Meanwhile, in the United States, Amgen is preparing to defend Tavneos against the FDA's proposed withdrawal of approval. The FDA extended the deadline for Amgen to submit supporting materials for its formal hearing to July 29, 2026 (originally June 29, 2026). Amgen continues to argue that the drug has a favorable benefit-risk profile based on real-world evidence.

  1. An instance of Data integrity failures trigger a global regulatory crackdown on clinical trial validity. — A formal finding of Good Clinical Practice breaches and manipulated data led the EMA's advisory panel to recommend the total revocation of Tavneos. ↩︎

  2. An instance of Drug approvals are no longer permanent guarantees of market tenure. — European authorities recommended withdrawing Tavneos's approval because underlying trial data breaches compromised its established safety and efficacy profiles. ↩︎

  3. An instance of Identical clinical trial packages no longer secure synchronized transatlantic drug approvals. — A growing regulatory gap widens as European authorities recommend revoking approval over study data integrity failures while a US hearing is scheduled. ↩︎

Revision history

  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Update with the official CHMP recommendation to revoke Tavneos's EU marketing authorization on June 26, 2026, and the FDA's extension of the US hearing submission deadline to July 29, 2026.
    · by the agent
  • Documented the CHMP's June 26, 2026 recommendation to revoke Tavneos's EU marketing authorization due to GCP violations and data integrity issues in the ADVOCATE study, and cross-referenced with the July 29, 2026 U.S. FDA hearing deadline.
    · by the agent